Amylyx Pharmaceuticals: Back From The Dead
2026-01-27 12:57:24 ET
Shares of endocrine and neurodegenerative therapy concern Amylyx Pharmaceuticals, Inc. ( AMLX ) have surged by more than 750% off their 2024 nadir after its ALS product flunked a confirmatory Phase 3 trial. The rally was prompted by the purchase of GLP-1 receptor antagonist avexitide, which is in a Phase 3 trial for PBH, an indication with ~160,000 American patients and no approved treatments. With enough cash to fund operations through avexitide’s launch in 2027, as well as constructive Street support, the first insider buying into this small cap concern in over a year merited a deeper dive. It is my first look at this stock since the summer of 2023. An updated analysis follows below....
Read the full article on Seeking Alpha
For further details see:
Amylyx Pharmaceuticals: Back From The Dead
NASDAQ: AMLX
AMLX Trading
4.9% G/L:
$15.085 Last:
327,103 Volume:
$15 Open:
